ImmunAb Research is advancing a new generation of precision-engineered CAR-T cell therapies to combat the deadly progression of cancer. Led by Dr. Christopher E. Rudd, an internationally recognized immunologist, ImmunAb brings together world-class science and translational expertise to transform how solid tumors are treated.

Our mission is simple: to translate breakthrough immunology into transformative therapies that improve outcomes and reduce side effects.

At our laboratories within adMare BioInnovations, we’re developing two patent-protected CAR-T platforms that have demonstrated 5–10× greater tumor clearance in preclinical lymphoma and melanoma models.

• Novel CAR architectures derived from viral immunology research (PCT WO 2023/021494 A1)
• Modulation of the Rasal1 immune regulator to boost tumor killing without added toxicity

With strong IP, cutting-edge facilities, and a clear translational path, ImmunAb is poised to lead the next wave of CAR-T innovation.

ImmunAb Research

Org chart

Teams

Offices